Advice
NICE is unable to make a recommendation about the use in the NHS of lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphomas after first-line chemotherapy in adults when a stem cell transplant is unsuitable. This is because Bristol-Myers Squibb has confirmed that it does not intend to make an evidence submission for the appraisal. Bristol-Myers Squibb considers that there is unlikely to be enough evidence that the technology is a cost-effective use of NHS resources in this population.
Information
If NHS organisations wish to consider lisocabtagene maraleucel for this indication, they should follow the advice on rational local decision making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when there is no NICE guidance.
NICE will review the position if the company decides that it wants to make an evidence submission.
ISBN: 978-1-4731-7124-4